Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.80% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2019-02-06
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 1.27%, a 15.45% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.10%, a 26.67% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.10%, a 8.33% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.50%, a 11.76% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.80%, a 49.73% increase from fiscal 2017.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 1.87%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 1.23%, a 12.14% decline from fiscal 2016.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.40%, a 17.65% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | 2.80% 10-K · filed 2019-02-06 | |||||
| 2018-09-30 | 2.80% 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | 2.80% 10-Q · filed 2018-08-10 | |||||
| 2017-12-31 | 1.87% 10-K · filed 2019-02-06 | |||||
| 2017-09-30 | 1.87% 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | 1.87% 10-Q · filed 2018-08-10 | 1.23% 10-K · filed 2017-09-01 | ||||
| 2017-03-31 | 1.27% 10-Q · filed 2017-05-08 | 1.19% 10-Q · filed 2017-05-08 | ||||
| 2016-09-30 | 1.10% 10-Q · filed 2016-11-08 | |||||
| 2016-06-30 | 1.40% 10-K · filed 2017-09-01 | |||||
| 2016-03-31 | 1.10% 10-Q · filed 2017-05-08 | 1.50% 10-Q · filed 2017-05-08 | ||||
| 2015-09-30 | 1.50% 10-Q · filed 2016-11-08 | |||||
| 2015-06-30 | 1.70% 10-K · filed 2016-09-13 | |||||
| 2015-03-31 | 1.20% 10-Q · filed 2015-05-08 | 1.70% 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | 1.70% 10-Q · filed 2015-02-06 | 1.70% 10-Q · filed 2015-02-06 | ||||
| 2014-09-30 | 1.70% 10-Q · filed 2015-11-06 | |||||
| 2014-06-30 | 1.50% 10-K · filed 2016-09-13 | |||||
| 2014-03-31 | 1.60% 10-Q · filed 2015-05-08 | 1.50% 10-Q · filed 2015-05-08 | ||||
| 2013-12-31 | 1.40% 10-Q · filed 2015-02-06 | 1.49% 10-Q · filed 2015-02-06 | 1.40% 10-Q · filed 2014-02-10 | |||
| 2013-06-30 | 1.50% 10-K · filed 2015-09-11 | |||||
| 2013-03-31 | 0.65% 10-Q · filed 2014-05-12 | |||||
| 2012-12-31 | 0.65% 10-Q · filed 2014-02-10 | 0.65% 10-Q · filed 2014-02-10 | ||||
| 2012-11-12 | 0.65% 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |